Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0F4SY
|
||||
| Former ID |
DIB014244
|
||||
| Drug Name |
Pridopidine
|
||||
| Synonyms |
Huntexil; Pridopidine hydrochloride; ACR-16; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Huntington's disease [ICD9: 294.1, 333.4; ICD10:F02.2, G10] | Phase 3 | [1] | ||
| Company |
Teva pharmaceutical
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H23NO2S
|
||||
| Canonical SMILES |
S(=O)(=O)(c1cc(C2CCN(CC2)CCC)ccc1)C
|
||||
| CAS Number |
CAS 346688-38-8
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00665223) A Study of Treatment With ACR16 in Patients With Huntington's Disease. U.S. National Institutes of Health. | ||||
| REF 2 | Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.